Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

New concept could improve cancer drug delivery

Researchers have developed a concept to potentially improve delivery of drugs for cancer treatment using nanoparticles that concentrate and expand in the presence of higher acidity found in tumor cells.

11 Jul 2013

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

Researchers discover potential biomarkers that track progression of neurodegenerative disease

A hallmark of neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's is that by the time symptoms appear, significant brain damage has already occurred-and currently there are no treatments that can reverse it.

9 Jul 2013

Scientists explore biomedical applications in implants, drug delivery for hydrogel

It's squishy, synthetic, flexible, mostly water and almost as tough as rubber. No, it's not "flubber" - it's a hydrogel, and now scientists at The University of Akron are exploring new biomedical uses for this polymer-based product.

6 Jul 2013

Saltwater-treatment for cystic fibrosis: an interview with Matthew Allen, Program Director at Cambridge Consultants

A group of Australian researchers, back in 2006, noted that there was a link between the severity of cystic fibrosis between sufferers who surfed, and sufferers who did not surf – and obviously Australia is a good place to spot that.

4 Jul 2013

FDA approves Orexo's Zubsolv for people suffering from opioid dependence

Orexo today announced that it has received approval from the U.S. Food and Drug Administration for Zubsolv (buprenorphine/naloxone) sublingual tablet CIII.

4 Jul 2013

West Pharmaceutical Services expands NovaGuard portfolio of needle safety products

West Pharmaceutical Services, Inc., a leading global developer and manufacturer of components and systems for injectable drug delivery, today announced the expansion of the NovaGuard portfolio of needle safety products.

2 Jul 2013

Researchers develop new drug delivery systems to treat cancer by blocking signaling receptor

A cardiac hormone signaling receptor abundantly expressed both in inflamed tissues and cancers appears to recruit stem cells that form the blood vessels needed to feed tumor growth, reports a new study by scientists at the University of South Florida Nanomedicine Research Center.

30 Jun 2013

Study shows "bioadhesive" coating can increase intestinal uptake of protein-based drugs

For protein-based drugs such as insulin to be taken orally rather than injected, bioengineers need to find a way to shuttle them safely through the stomach to the small intestine where they can be absorbed and distributed by the bloodstream.

28 Jun 2013

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

When you take a medicine you may want the drug to all be released immediately or perhaps more slowly over a longer period of time. If we can make a medicine where we control the release then we can tailor our medicines to release at the exact rate we choose that is best for the patient.

26 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Slipping bacteria some silver could give old antibiotics new life, scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University reported June 19 in Science Translational Medicine.

20 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

Orexo announces dosing of first patient with Zubsolv in phase III clinical study

Orexo AB announces today that the first patient has been dosed with Zubsolv in a phase III study for a new clinical indication for Zubsolv.

17 Jun 2013

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence issued draft guidance recommending ILUVIEN for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema considered insufficiently responsive to available therapies.

15 Jun 2013

Drug Delivery News and Research

Further Reading

New concept could improve cancer drug delivery

Cancer immunotherapies promise to be a new tool in fight against cancer

Researchers discover potential biomarkers that track progression of neurodegenerative disease

Scientists explore biomedical applications in implants, drug delivery for hydrogel

Saltwater-treatment for cystic fibrosis: an interview with Matthew Allen, Program Director at Cambridge Consultants

FDA approves Orexo's Zubsolv for people suffering from opioid dependence

West Pharmaceutical Services expands NovaGuard portfolio of needle safety products

Researchers develop new drug delivery systems to treat cancer by blocking signaling receptor

Study shows "bioadhesive" coating can increase intestinal uptake of protein-based drugs

Controlled drug release using novel excipients: an interview with Dr Laura Waters, University of Huddersfield

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

Orexo announces dosing of first patient with Zubsolv in phase III clinical study

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

Researchers develop nano-volcanoes that hold promise for new drug-delivery technologies

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Hebrew University student develops drug formulations to treat illnesses through skin applications

BioDelivery Sciences International submits BUNAVAIL NDA to FDA

Event guide: World ADC San Diego eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo